Relapsed / Refractory B-Acute Lymphocytic Leukemia (ALL) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032


 B-Cell Acute lymphoblastic leukemia (ALL) is a type of blood cancer in which many abnormal, immature lymphocytes known as blasts begin to multiply in the bone marrow. Lymphocytes are white blood cells that play a role in the immune response. B-ALL is characterized by the expression of various B–cell-specific antigens, which often include PAX-5, CD19, CD20, CD22, CD24, and CD79a. B-cell ALL is primarily a childhood disease, with approximately 75% of cases being children aged <6 years, however, the majority of the B-Cell ALL occurs in the <15 years of age; also, the peak of the incidence is seen in people around 40 years. Approximately 20% to 30% of adult acute lymphoblastic leukemias (ALLs) and 5% of pediatric ALLs harbor the Ph-chromosome. This genetic alteration confers a poor prognosis, as defined by shorter remission duration and shorter survival, and higher rates of resistance to standard chemotherapy. CNS involvement is more common in relapsed adult patients. In children, the overall complete remission rate is greater than 95%, and in adults, the rate is 60-85 percent. Relapse occurs in 15 to 20% of children with B-cell ALL, and the prognosis becomes less favorable. Adults with B-cell ALL have a relapse rate of approximately 50%, and a poor prognosis is expected, with a median survival of fewer than six months after relapse.

In children with ALL, 80% to 85% of ALL consists of early B-cells, and approximately 2% are mature B-cells. In adults with ALL, 75% of cases are early B-cells, and 25% are malignant early T-cells.

 

The competitive landscape of Relapsed / Refractory B-Acute Lymphocytic Leukemia (ALL) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Relapsed / Refractory B-Acute Lymphocytic Leukemia (ALL) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed / Refractory B-Acute Lymphocytic Leukemia (ALL) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Relapsed / Refractory B-Acute Lymphocytic Leukemia (ALL) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. no    Asset   Company         Stage

1          FELIX   Autolus Therapeutics plc            Phase 2

2          Palbociclib         Pfizer    Phase 1

3          Blinatumomab   Pharmacyclics LLC.       Phase 2

4          TBI-1501          Takara Bio Inc.  Phase 2

5          UCART19         Servier  Phase 1

6          CD19 CAR-T     Hebei Senlang Biotechnology Inc., Ltd.   Phase 1

7          ADCT-602         ADC Therapeutics S.A.  Phase 2

8          CD19-CART      PersonGen BioTherapeutics      Phase 1

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more